Foundayo vs Zepbound
Eli Lilly's Oral Pill vs Its Tirzepatide Injection (2026)
Both Foundayo and Zepbound are Eli Lilly weight-loss drugs — but they sit at opposite ends of the convenience-vs-power trade-off. Foundayo (orforglipron) is a daily oral GLP-1 pill with no fasting. Zepbound (tirzepatide) is a once-weekly dual GLP-1/GIP injection with the higher weight-loss ceiling. Here's how to choose.
Foundayo vs Zepbound: At a Glance
- ✓Non-peptide oral GLP-1 pill (GLP-1 only)
- ✓Once daily — any time, with or without food
- ✓No injection, no fasting, room-temperature storage
- ✓Phase 2 ~14.7% weight loss; ATTAIN-1 up to 27.3 lbs
- ✓Self-pay from ~$149/mo (lowest dose)
- ✓Eli Lilly — FDA approved April 2026
- ✓Dual GLP-1/GIP injectable
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for obesity and sleep apnea
- ✓SURMOUNT-1: ~20.9% weight loss at 72 weeks (15 mg)
- ✓Refrigerated; injection-site rotation needed
- ✓Eli Lilly — widely available now
Detailed Comparison
| Feature | Foundayo (Orforglipron) | Zepbound (Tirzepatide) |
|---|---|---|
| Manufacturer | Eli Lilly | Eli LillyBest |
| Drug Type | Non-peptide small molecule | Peptide dual agonist |
| Mechanism | GLP-1 only | GLP-1 + GIP |
| Administration | Once-daily pill | Once-weekly injection |
| Fasting/Timing | None | N/A (injection) |
| Weight Loss | Phase 2 ~14.7%; up to 27.3 lbs | ~20.9% at 72 weeks (15 mg) |
| Extra Indications | None yet | Obstructive sleep apnea |
| Storage | Room temperature | Refrigerated until use |
| Needles | No | Yes (weekly) |
| FDA Status | Approved April 2026 | Approved (obesity 2023) |
Convenience vs Power
Maximum Weight Loss
Zepbound has the higher ceiling (~20.9% at 72 weeks) thanks to its dual GLP-1/GIP mechanism. If raw efficacy is the priority, the injection leads.
No Needles
Foundayo is a daily pill — no injections, no sharps, no site rotation. For needle-averse patients, that can be decisive.
Travel & Storage
Foundayo is room-temperature; Zepbound needs refrigeration and cold-chain handling. Foundayo wins for travel.
Proven Track Record
Zepbound has multi-year data and a sleep-apnea indication. Foundayo is newer but simpler to take.
Dosing Routine
Foundayo: a pill every day. Zepbound: one injection a week. Pick the rhythm you'll actually keep.
Cost
Foundayo self-pay starts ~$149/mo (lowest dose). Zepbound is pricier without coverage. Check savings cards for both.
Which Should You Choose?
This is a classic convenience-versus-power decision, and both options come from the same company. Zepbound (tirzepatide) is the more powerful drug — its dual GLP-1/GIP mechanism produced about 20.9% weight loss over 72 weeks, and it carries a sleep-apnea indication on top of obesity. The cost is a weekly injection and refrigeration.
Foundayo (orforglipron) trades some of that ceiling for radical simplicity: a daily pill you can take any time, store at room temperature, and travel with easily — and at a lower self-pay entry price. For people who would not start or stick with injections, that trade can be worth it.
A reasonable framing: if you want the most weight loss and don't mind a weekly shot, Zepbound. If you want effective weight loss without needles or refrigeration, Foundayo. Track whichever you start in Shotlee so you can see your real response — and compare cleanly if you ever switch between Lilly's two options.
Foundayo vs Zepbound: Frequently Asked Questions
Zepbound (tirzepatide) has the higher weight-loss ceiling — about 20.9% at 72 weeks (15 mg) thanks to its dual GLP-1/GIP mechanism. Foundayo (orforglipron) showed ~14.7% in Phase 2 (up to 27.3 lbs at higher doses). Zepbound is more powerful; Foundayo is a needle-free pill.
Yes — both are Eli Lilly products. Foundayo is the oral orforglipron pill; Zepbound is the injectable tirzepatide. Lilly offers both an oral and an injectable weight-loss option.
No. Foundayo is a once-daily pill taken any time with or without food. Zepbound is a once-weekly subcutaneous injection that requires refrigeration and injection-site rotation.
Only under medical guidance. People switch for convenience (no needles, room-temperature storage, lower self-pay cost), but Zepbound generally produces more weight loss. Track both in Shotlee to compare your own response.
Yes. Shotlee tracks oral and injectable GLP-1s — dose, weight, and side effects — so you can compare the two on your own data.
Track Foundayo or Zepbound in Shotlee
Free dose logging, weight trends, and side-effect tracking for oral and injectable GLP-1s.
📚References & sources
Latest on Foundayo
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read